Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.
1998
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Deep venous thrombosis in postoperative vascular surgical patients: A frequent finding without prophylaxis
2001
Anticoagulant Use in Patients with Chronic Renal Impairment
2005
A Meta-Analysis of Thromboembolic Prophylaxis Following Elective Total Hip Arthroplasty*
2000
Regional anesthesia in the anticoagulated patient: Defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation)
2003
Thromboembolic Disease Prophylaxis in Patients With Hip Fracture
2005
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment
2008
A Comparison of Hirudin with Heparin in the Prevention of Restenosis after Coronary Angioplasty
1995
Nonadherence in outpatient thromboprophylaxis after major orthopedic surgery: a systematic review
2010
Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis
2002
Total Achilles Tendon Rupture
1998
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery
2001
Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross‐sectional study in Brazil
2006
Heparin-Induced Thrombocytopenia
2000
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
2010
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects
2006
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
2008
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Low Molecular Weight Heparin
1997
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
2010
Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis
2003 Standout
Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery
2003
Prevention of venous thromboembolism
2001
New oral antithrombotics: a need for laboratory monitoring. For
2010
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
2010
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
2010 StandoutNobel
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
2011
Prevention of VTE in Orthopedic Surgery Patients
2012 Standout
Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate
2008
Drug-Induced Liver Injury in Humans: The Case of Ximelagatran
2009
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
2004
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
2005
Diagnosis of osteoporosis and assessment of fracture risk
2002 Standout
Oral Anticoagulant Therapy
2012 Standout
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
2008
Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery<subtitle>A Meta-analysis of 4 Randomized Double-blind Studies</subtitle>
2002
Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran
2008
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial
2002
New Antithrombotic Drugs
2012
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
2008
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
2009
Rivaroxaban
2011
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
2010
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2008 Standout
Duration of Prophylaxis Against Venous Thromboembolism With Fondaparinux After Hip Fracture Surgery<subtitle>A Multicenter, Randomized, Placebo-Controlled, Double-blind Study</subtitle>
2003
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty
2010
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
2005
Efficacy and Safety of Weight-Adapted Nadroparin Calcium vs. Heparin Sodium in Prevention of Clinically Evident Thromboembolic Complications in 1,190 General Surgical Patients
2000
Temporal Aspects of Heparin-Induced Thrombocytopenia
2001 Standout
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients
2000
Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement
2003
Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients
2003
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Duration of Venous Thromboembolism Prophylaxis After Surgery
2003
Prevention of fatal pulmonary embolism and mortality in surgical patients
2005
Thromboprophylaxis with 60 mg Enoxaparin Is Safe in Hip Trauma Surgery
2001
Comprehensive Deep Venous Thrombosis Prevention Strategy After Total-Knee Arthroplasty
2003
Incidence of DVT following Surgery of the Foot and Ankle
2002
A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients
2004
The Benefit of Aspirin Chemoprophylaxis for Thromboembolism after Total Knee Arthroplasty
2006
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
Bivalent direct thrombin inhibitors: hirudin and bivalirudin
2004
Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
2005
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery
2007
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
2010
Perioperative venous thromboembolism prophylaxis in Israel: a survey of academic surgical departments
2004
The Assessment of Deep Vein Thromboses for Therapeutic Trials
2003
Stroke
2008 Standout
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement
2010
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
2007
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects
2009
Heparin-Induced Thrombocytopenia
2006 Standout
A Prospective Study of Venous Thromboembolism after Major Trauma
1994 Standout
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
2007
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Clinical relevance of the fibrinogen uptake test in patients undergoing elective general abdominal surgery—relation to major thromboembolism and mortality
1995
Preoperative or Postoperative Start of Prophylaxis for Venous Thromboembolism With Low-Molecular-Weight Heparin in Elective Hip Surgery?
2002
Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
2009
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
2010
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
2002 Standout
Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications
2008
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients
2000
PROPHYLAXIS OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM
1998
New Anticoagulant Agents: Direct Thrombin Inhibitors
2008
Prevention of Venous Thromboembolism
2004 Standout
Heparin and Low-Molecular-Weight Heparin
1998
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Antithrombotic Therapy in Atrial Fibrillation
2004
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin
2006
Pre-eclampsia
2010 Standout
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement
2001
Neuraxial Anesthesia and Low-Molecular-Weight Heparin Prophylaxis in Major Orthopedic Surgery in the Wake of the Latest American Society of Regional Anesthesia Guidelines
2005
Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone
2014 StandoutNature
A New Therapeutic Option by Subcutaneous Recombinant Hirudin in Patients with Heparin-induced Thrombocytopenia Type II
2000
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial
2003
Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors
2005
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1
2007
Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies
2002
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
2007 Standout
Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points
2004
Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement
2002
A Comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis against Deep-Vein Thrombosis after Hip or Knee Implantation
1993
Idarucizumab for Dabigatran Reversal
2015 Standout
Prevention of Venous Thromboembolism
2008 Standout
Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification
2010
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
2003
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study
2003
Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity
2006
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study
2007
Angiogenesis in Fracture Repair
1998
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
2009
Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation
2012
Deep vein thrombosis
2005
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
2013
Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery
2007
A dose‐ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty
2010
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison
2002
Preoperative vs Postoperative Initiation of Low-Molecular-Weight Heparin Prophylaxis Against Venous Thromboembolism in Patients Undergoing Elective Hip Replacement
1999
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement
2003
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)
2011
Prevention of Deep-Vein Thrombosis after Total Hip Arthroplasty
1997
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
2010 StandoutNobel
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta‐analysis
2004
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review
2004
Prevention of Venous Thromboembolism
1998
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban
2010
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
New antithrombotic agents
1999
Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects
2007
Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
2006
Antithrombotic Therapy in Atrial Fibrillation
2008
Low Rate of Venous Thromboembolism After Craniotomy for Brain Tumor Using Multimodality Prophylaxis
2002
Dabigatran Association With Higher Risk of Acute Coronary Events
2012
Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393
1996
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty
2010
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty
2001
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
1998 Standout
Is Color-Flow Duplex a Good Diagnostic Test for Detection of Isolated Calf Vein Thrombosis in High-Risk Patients?
2000
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
2004
Post Discharge Clinically Overt Venous Thromboembolism in Orthopaedic Surgery Patients with Negative Venography -an Overview Analysis
1996
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
2008
Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats
2007
Low Molecular Weight Heparin
1997
Ximelagatran and melagatran vs. low‐molecular‐weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration
2005
Noninvasive assessment of bone mineral and structure: State of the art
1996
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Factor V Leiden (G1691A) and Prothrombin Gene G20210A Mutations as Potential Risk Factors for Venous Thromboembolism after Total Hip or Total Knee Replacement Surgery
2002 StandoutNobel
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
2003
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Perioperative low-molecular-weight heparin. Is it effective and safe
1995
Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
1999
Natural History of Venous Thromboembolism
2003
Lessons From Ximelagatran: Issues for Future Studies Evaluating New Oral Direct Thrombin Inhibitors for Venous Thromboembolism Prophylaxis in Orthopedic Surgery
2008
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism
2012
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY
2005
Prophylaxis of postoperative thromboembolism with low molecular weight heparins
1993
Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance
2000
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation
2007
Duplex Ultrasonography for the Detection of Deep Vein Thrombi After Total Hip or Knee Arthroplasty
1993
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials
2009
Low Frequency of Phlebographic Deep Vein Thrombosis After Laparoscopic Cholecystectomy—A Pilot Study
2006
Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery
2005
A Comparison of Compression Ultrasound With Color Doppler Ultrasound for the Diagnosis of Symptomless Postoperative Deep Vein Thrombosis
1997
Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
2005
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review.
2001
A Meta-analysis of Methods to Prevent Venous Thromboembolism Following Total Hip Replacement
1994
Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance
2003
Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty
2002
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Generation of Anti-Hirudin Antibodies in Heparin-Induced Thrombocytopenic Patients Treated With R-Hirudin
1999
Noninvasive Diagnosis of Deep Venous Thrombosis
1998
Graduated compression stockings: knee length or thigh length.
2001
Low Molecular Weight Heparin Decreases Proximal and Distal Deep Venous Thrombosis Following Total Knee Arthroplasty
1998
Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin.
1999
Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
2008
Low-Molecular-Weight Heparins
1997 Standout
Graduated Compression Stockings
2001
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
1994
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
2002
Diagnostic Accuracy of Compression Ultrasonography for the Detection of Asymptomatic Deep Venous Thrombosis in Medical Patients
2001
The Halogen Bond
2016 Standout
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)
2007
Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta-analyses
1997
Prevention of deep-vein thrombosis after total hip and knee replacement
2004
Prevention of Venous Thromboembolism
1995
Design, Structure−Activity Relationships, X-ray Crystal Structure, and Energetic Contributions of a Critical P1 Pharmacophore: 3-Chloroindole-7-yl-Based Factor Xa Inhibitors
2008
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Prevention of Deep Vein Thrombosis after Hip Replacement
1999
Comparison of Warfarin and External Pneumatic Compression in Prevention of Venous Thrombosis After Total Hip Replacement
1992
Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
2005
Rivaroxaban: A New Oral Factor Xa Inhibitor
2010
Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial.
2008
Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use.
2008
Oral Delivery of Anticoagulant Doses of Heparin
1998
Works of Peter Kälebo being referenced
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies
2007
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I
2004
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial
2002
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX‐2)
2010
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
2008
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
2007
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
2005
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study
2003
Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement
2005
Prevention of Thromboembolism with Use of Recombinant Hirudin. Results of a Double-Blind, Multicenter Trial Comparing the Efficacy of Desirudin (Revasc) with That of Unfractionated Heparin in Patients Having a Total Hip Replacement*
1997
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery
2007
A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement
1997
Is Colour Doppler Ultrasound a Sensitive Screening Method in Diagnosing Deep Vein Thrombosis after Hip Surgery ?
1996
Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.
2006
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
2008
Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials
1997
A Dose-ranging Study of the Oral Direct Thrombin Inhibitor, Ximelagatran, and Its Subcutaneous Form, Melagatran, Compared with Dalteparin in the Prophylaxis of Thromboembolism after Hip or Knee Replacement: METHRO I
2002
Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin.
1991
Soft-Tissue Radiography, Computed Tomography, and Ultrasonography of Partial Achilles Tendon Ruptures
1990
Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.
2005
Phlebographic findings in venous thrombosis following total hip replacement
1990
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
2006
Percentage of Inadequate Phlebograms and Observer Agreement in Thromboprophylactic Multicenter Trials Using Standardized Methodology and Central Assessment
1996
VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.
2005
Bone repair in implant models: a review with emphasis on the harvest chamber for bone regeneration studies.
1989
Bone Mass Determination from Microradiographs by Computer-Assisted Videodensitometry
1988
Direct Thrombin Inhibition with Rec-Hirudin CGP 39393 as Prophylaxis of Thromboembolie Complications after Total Hip Replacement
1994
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial
2007
Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.
2007
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement
2002
Phlebographic Findings in Venous Thrombosis following Total Hip Replacement
1990
Bone Mass Determination from Microradiographs by Computer-Assisted Videodensitometry
1988